GlassScriptPhysician profile
Douglas D Min
NPI 1316927809
$10,447.95
in general payments reported to CMS, 2019-2025
36 companies · $1,741 in 2025
The $1,741 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,649 · 2020: $881 · 2021: $1,361 · 2022: $1,838 · 2023: $1,581 · 2024: $1,397 · 2025: $1,741.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,718.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,718.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $2,058.35 | 2019-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $1,725.47 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $1,452.04 | 2019-2025 | Trelegy Ellipta, Nucala |
| Genzyme Corporation | $705.74 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $648.43 | 2021-2025 | Cuvitru, Takhzyro, Eohilia |
| Kaleo, INC. | $572.87 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $331.25 | 2019-2022 | |
| Covis Pharma Gmbh | $325.07 | 2019-2023 | |
| Optinose US, INC. | $309.11 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $299.78 | 2020-2023 | Stiolto Respimat, Spiriva Respimat |
| Novartis Pharmaceuticals Corporation | $286.25 | 2019-2025 | |
| Alk-Abello, INC | $206.90 | 2019-2023 | Odactra, Grastek, Ragwitek |
| Regeneron Pharmaceuticals, INC. | $203.55 | 2019-2022 | |
| Pfizer INC. | $192.97 | 2021-2022 | |
| Amgen INC. | $144.73 | 2022-2025 | Tezspire |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $116.38 | 2021-2025 | Xembify |
| Teva Pharmaceuticals USA, INC. | $94.34 | 2020-2022 | |
| Csl Behring | $88.28 | 2022-2024 | Hizentra, Privigen |
| Integra Lifesciences Corporation | $82.56 | 2025 | Inspira Air, Acclarent Aera, Trudi Probe |
| Octapharma USA, INC. | $69.97 | 2022-2025 | Cutaquig |
| Ars Pharmaceuticals Operations, INC. | $67.54 | 2025 | Neffy |
| Phadia US INC. | $59.60 | 2021 | |
| Hospira, INC. | $54.09 | 2023-2025 | |
| Leo Pharma INC. | $50.75 | 2022-2023 | Adbry |
| Galderma Laboratories, L.P. | $39.42 | 2025 | Nemluvio |
| Blueprint Medicines Corporation | $38.35 | 2024-2025 | Ayvakit |
| Gc Biopharma USA, INC. | $30.14 | 2025 | Alyglo |
| Electromed, INC. | $30.03 | 2021 | |
| Sanofi Pasteur INC. | $29.45 | 2019-2020 | |
| Inspire Medical Systems, INC. | $26.80 | 2025 | Inspire |
| Hikma Pharmaceuticals USA | $22.89 | 2023 | Ryaltris |
| Pharming Healthcare, INC. | $19.92 | 2023 | Ruconest |
| Shire North American Group INC | $17.95 | 2019 | |
| Greer Laboratories, INC. | $16.34 | 2019 | |
| Genentech USA, INC. | $16.32 | 2019 | |
| Biocryst US Sales Co., LLC | $14.32 | 2023 | Orladeyo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Min listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.